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Abstract: The 10-valent pneumococcal vaccine was introduced in Pakistan’s Expanded Program
on Immunization (EPI) in 2013 as a 3 + 0 schedule without catchup. We conducted three annual
cross-sectional surveys from 2014–2016 to measure vaccine-type (VT) carriage in infants from a rural
part of Pakistan. Nasopharyngeal specimens were collected by random sampling of infants from
two union councils of Matiari. Samples were then transported to the Infectious Disease Research
Laboratory (IDRL) at the Aga Khan University within 6–8 h of collection. Serotypes were established
using sequential multiplex PCR. Of the 665 children enrolled across three surveys, 547 were culturepositive for pneumococcus. VT carriage decreased from 21.8% in 2014 to 12.7% in 2016 (p-value for
trend <0.001). Those who were not vaccinated or partially vaccinated were found to be at higher
risk of carrying a VT serotype ((aOR 2.53, 95% CI 1.39, 4.63 for non-vaccinated) and (aOR 3.35, 95%
CI 1.82, 6.16 for partially vaccinated)). On the other hand, being enrolled in the most recent survey
was negatively associated with VT carriage (aOR 0.51, 95% CI 0.28, 0.93). We found that PCV10 was
effective in decreasing the carriage of vaccine-type serotypes in Pakistani infants.
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1. Introduction
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Pneumonia is a major cause of childhood morbidity and mortality worldwide. It has
several etiologies of which Streptococcus pneumoniae (pneumococcus) is a leading one [1].
Pneumococci are Gram-positive bacteria, accountable for a wide spectrum of diseases both
invasive (including pneumonia, bacteremia, and meningitis) and non-invasive [2].
Globally, the incidence of invasive pneumococcal disease in children under 5 years of
age was about 14.5 million cases (uncertainty range 11.1–18.0 million) in 2000, resulting in
almost 826,000 (582,000–926,000) deaths [3]. During the Millennium Development Goal
(MDG) years of 2000–2015, the pneumococcal disease burden decreased globally, but its
incidence increased in third world countries [4]. In 2015, Pakistan accounted for 7.1 million
(4.2–12.0 million) pneumococcal pneumonia cases and around 63,960 pneumonia deaths in
children less than 5 years of age [4].
There are more than 100 known serotypes of pneumococcus, which asymptomatically colonize the human respiratory tract. Out of these, only a few serotypes cause the
majority of the disease [5,6]. Two Pneumococcal Conjugate Vaccine (PCV) formulations
are currently WHO-prequalified for use in children: a 10-valent PCV (GSK, SynflorixTM )
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containing serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, and a 13-valent PCV (Pfizer,
Prevenar 13® ) containing three serotypes, 3, 6A, and 19A, in addition to PCV10 serotypes.
Both PCV10 and PCV13 have proven to be the cornerstone of prevention against invasive pneumococcal disease worldwide [7–10]. Until 2020, PCVs had been introduced in
146 countries out of which in 60 countries it had been introduced with the help of Gavi,
The Vaccine Alliance [11]. Another 10-valent PCV (PNEUMOSIL, Serum Institute of India,
SIIPL-PCV) targeting serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A, and 6B has recently been
WHO pre-qualified [12,13]. Other higher valency PCV products (15-valent, 20-valent, and
pan-serotype vaccines) are at various phases of development [14,15].
Pakistan was the first South Asian country to introduce PCV10 in its Expanded Program on Immunization (EPI) with the assistance of Gavi, The Vaccine Alliance in 2012 [16].
To match the existing immunization schedule, PCV10 was introduced as a 3 + 0 regimen,
with doses at 6, 10, and 14 weeks of life without catch-up immunization [7,17]. The ten
serotypes present in PCV10 are thus referred to as vaccine type (VT) serotypes.
As more data became available on prevailing serotypes in carriage and disease isolates
in south Asia, PCV10 was replaced with PCV13 in the EPI of Pakistan in early 2021 [18].
This data-driven policy decision illustrates the importance of the continuous monitoring of
prevailing serotypes after the introduction of vaccines. Since invasive disease has become
rare in the post-vaccine scenario, nasopharyngeal carriage can provide important insights
into the changing pneumococcal sero-epidemiology [19]. Thus, we carried out a series
of cross-sectional surveys in two union councils of the rural Matiari district in the Sindh
province, where we had nasopharyngeal carriage estimates available from the time before
the introduction of the vaccine. The objectives were to measure the direct effect of conjugate
vaccine on the prevalence of vaccine type serotypes in children who received the vaccine,
as well as to measure the indirect effect in children who did not receive the vaccine. We
also looked at factors associated with overall and VT carriage.
2. Materials and Methods
2.1. Study Design and Setting
This was a series of cross-sectional surveys conducted at yearly intervals for three years
after the introduction of PCV10 in two union councils of rural Matiari (Khyber and Shah
Alam Shah Jee Wasi), in the southern province of Sindh, Pakistan. A union council is
the smallest administrative unit in the government structure. These sites were selected
because the baseline study before vaccine introduction was done in the same population.
Matiari is about 180 km away from Aga Khan University (AKU) in Karachi, where the
research unit and the Infectious Disease Research Laboratory (IDRL) are located. Samples
were collected from 1 January to 2 February in 2013 (phase 1, pre-PCV introduction),
14 February to 14 March 2014 (phase 2), 17 January to 3 March 2015 (phase 3) and 23 January
to 14 March 2016 (phase 4). All the samples were collected approximately at the same time
every year to account for seasonal variation in carriage rates. A random sample was drawn
from a pre-existing line listing of children of selected union councils. All children aged 3 to
12 months residing in the study area were eligible to be enrolled.
Those excluded from the study were children with a history of severe acute respiratory
illness in the last 2 weeks, the presence of one or more of the following symptoms: presence
of chest wall indrawing, blue skin discoloration (cyanosis) and fast breathing, children
with moderate-to-severe cerebral palsy, children with neurological disorders affecting
swallowing, and those with nose and throat disorders. If a child selected from the random
list was not found or not eligible, the next eligible child on the list was approached.
We updated the tool used in the baseline carriage survey to include information
regarding pneumococcal vaccines and any other subsequent vaccines introduced in the
Expanded Program on Immunization (EPI) since then. A two-day training session was
held for staff involved in the study to standardize data and specimen collection methods.
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2.2. Laboratory Methods
For the purpose of standardization, we used the same laboratory methods as in
the base-line carriage survey [20]. Briefly, nasopharyngeal swabs (MW173P Transwab®
Pernasal Amies Plain, Wales, UK) were collected by trained staff following World Health
Organization methods and immediately placed in skim milk tryptone glucose glycerol
(STGG) media (Karachi, Pakistan) [17]. These were then transported at 2–8 ◦ C within 6–8 h
of collection to IDRL at AKU in Karachi, where the samples were frozen upright at −80 ◦ C
until further processing. Batches of 20–40 samples were thawed, cultured, and sub-cultured
as mentioned in the CDC protocol [21].
Isolates were tested using conventional multiplex PCR to identify different pneumococcal serotypes [22]. DNA extraction was performed using the crude boiling method.
It included boiling the bacterial culture for 10 min and centrifugation (Hitachi, Chiyoda,
Tokyo, Japan) for another 10 min; the resulting supernatant was collected in a sterile microcentrifuge tube (Thermo Scientific, Waltham, MA, USA) and the remaining DNA extract
was used for PCR techniques. The cpsA gene as an internal positive control was added
in all multiplex reactions. An amount of 2 µL of DNA was added to the PCR master mix
containing nuclease-free water, 2X Qiagen multiplex PCR buffer, Qiagen Q solution (Qiagen
Multiplex Kit (Qiagen cat # 206145, Hilden, Germany), and 25 µM working stock of primers
(Eurofins MWG operon, Luxembourg city, Luxembourg).
Amplification was carried out in an Eppendorf Master Cycler Gradient, Hamburg, Germany, with the specific temperature profile, and the amplified PCR products were stained
and read under a BioRad Gel Doc imager (BioRad Universal Hood II, Hercules, CA, USA).
Serotypes were detected through sequential multiplex conventional PCR, which were
further confirmed by monoplex PCR, using the same PCR conditions, to avoid misidentification due to non-specific bands. Serogroup 6 was additionally differentiated into serotypes
6A, 6B, 6C, and 6D by same method used by Jin et al. with some modifications as mentioned
earlier [23]. Pneumococcal serotype controls added in each reaction were obtained from
the CDC streptococcal lab. The non-typeable products were confirmed by pneumococci
using lytA real time PCR per Carvalho et al. [24].
For quality control in the Optochin susceptibility and bile solubility reactions, Streptococcus pneumoniae ATCC 49619 and Enterococcus faecalis ATCC 29212 strains of American
Type Culture Collection (ATCC) were used.
2.3. Sample Size
The sample size was calculated based on a predicted decline in nasopharyngeal
carriage in upcoming years after the introduction of the vaccine. There were no recent data
regarding the prevalence of pneumococcal carriage in Pakistan, thus the sample size was
calculated on the basis of previously done surveys. To obtain the maximum sample size,
a baseline carriage rate of 50% was assumed. The sample size was calculated to be 220
for each round of annual surveys in order to show a decline in prevalence of 0·2 (from 0.5
to 0.3) after the introduction of the ten-valent vaccine with a 5% level of significance and
80% power.
2.4. Data Management and Quality Assurance
The questionnaire consisted of demographics, socio-economic indicators, and general
health status and was collected on paper forms by trained staff at the appointed sites.
All children who participated were given a unique identifier which was linked to an
identification number in the demographic surveillance system. All completed forms were
reviewed by the study supervisor at the end of the day for completeness and consistency.
PCV10 carriage was defined as isolation of any of the 10 serotypes included in PCV10
(serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F). Non-vaccine type (NVT) carriage was defined
as presence of all other pneumococci including the non-typeable. PCV13 serotypes were
defined as any of the PCV13 specific serotypes 3, 6A, and 19A. Infants who received all three
PCV10 doses were considered as fully vaccinated, those who received 1 or 2 doses were
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considered partially vaccinated, and those with no doses were considered unvaccinated.
Data entry was done using RedCap software, on which validation and consistency checks
were run. Analysis was done using STATA version 16.0. The general characteristics of
study participants are presented as mean (SD) or median (IQR) based on normality for
quantitative variables and numbers with percentages for categorical variables. For each
survey, we estimated the overall prevalence of pneumococcal carriage, PCV10 carriage,
PCV13 carriage, and non-vaccine serotypes with 95% confidence intervals (CIs). Logistic
regression was used to identify predictors associated with carriage. All variables found to
be significant at a p-value of ≤0.10 at the univariate level were added to the multivariate
model· A stepwise backward elimination approach was used to derive a parsimonious
model, retaining only variables with a p-value of <0.05. Odds ratios with 95% confidence
intervals are presented.
3. Results
We conducted a series of cross-sectional surveys for three consecutive years (2014–2016)
after PCV10 introduction. An earlier published pre-PCV10 introduction survey conducted
in 2013 in the same population and using the same methodology served as the baseline for
comparison [20]. In total 224, 221, and 220 children participated in the 2014, 2015, and 2016
surveys respectively. The baseline demographics and clinical characteristics of enrolled
children are presented in Table 1. The overall mean age of the participants was 7.24 ± 2.75
months, the majority of the children were male, and the majority of the primary caretakers
644 (84%) had no education at all; the median crowding index was 5.5 (4–7.5); around half
of children were exposed to environmental tobacco smoke (ETS).
Table 1. Sociodemographic characteristics of enrolled children.
Characteristics

2014

2015

2016

n = 224

n = 221

n = 220

7.1 ± 2.60

7.5 ± 2.7

7.8 ± 2.94

Male

108 (48.2%)

113 (51.1%)

113 (51.6%)

Female

116 (51.8%)

108 (48.9%)

106 (48.4%)

Illiterate

150 (81.1%)

119 (84.4%)

184 (84.8%)

1–5 Years

25 (13.5%)

17 (12.1%)

25 (11.5%)

6–16 Years

10 (5.4%)

5 (3.5%)

8 (3.7%)

122 (54.5%)

76 (42.0%)

128 (59.0%)

Age, months (Mean ± SD)
Gender

Education of Caretaker

Education of Primary wage earner
No Education
1–5 years

34 (15.2%)

61 (33.7%)

46 (21.2%)

6–16 years

68 (30.4%)

44 (24.3%)

43 (19.8%)

People in the household, Median (IQR)

8 (6–11.5)

8 (6–11)

8 (6–11)

No. of rooms in house, Median (IQR)

1 (1–2)

1 (1–2)

1 (1–2)

Crowding index, * Median (IQR)

6 (4–8)

5 (4–7)

5.5 (4–8)

None

206 (92.0%)

207 (93.7%)

217 (99.1%)

One

16 (7.1%)

12 (5.4%)

1 (0.5%)

Two or more

2 (0.9%)

2 (0.9%)

1 (0.5%)

Hospital Admissions in the last year
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Table 1. Cont.
Characteristics

2014

2015

2016

n = 224

n = 221

n = 220

None

118 (52.7%)

109 (49.5%)

166 (75.8%)

One

66 (29.5%)

58 (26.4%)

18 (8.2%)

Two or more

40 (17.9%)

53 (24.1%)

35 (16.0%)

Yes

136 (60.7%)

101 (45.7%)

101 (46.1%)

No

88 (39.3%)

120 (54.3%)

118 (53.9%)

Yes

179 (79.9%)

47 (21.3%)

66 (30.1%)

No

44 (19.6%)

174 (78.7%)

153 (69.9%)

1 (0.4%)

0 (0.0%)

0 (0.0%)

Yes

184 (82.1%)

165 (74.7%)

184 (83.6%)

No

40 (17.9%)

56 (25.3%)

36 (16.4%)

Outpatient visits in the last month

Smoker in household

Exposed to smoke during cooking

Don0 t

Know

Ever Vaccinated

IQR = Interquartile Range, * Defined as number of persons/number of rooms.
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All samples collected were of sufficient quality for analysis. Distributions of the most
prevalent VT and NVT serotypes for each year are presented in Figures 1 and 2. Total
6 of no
14
pneumococcal carriage remained relatively stable over time (range 79.5 to 81.8%), with
significant reduction noticed (p-value for trend 0.340 Table 2).

Figure 1. Proportion of children carrying PCV10, PCV13, and NVT serotypes over time. Rates for
Figure 1. Proportion of children carrying PCV10, PCV13, and NVT serotypes over time. Rates for
2013 are from a previously published survey in the same community by the same group of authors.
2013 are from a previously published survey in the same community by the same group of authors.
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Figure 1. Proportion of children carrying PCV10, PCV13, and NVT serotypes over time. Rates for
2013 are from a previously published survey in the same community by the same group of authors.
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children 3–12 months old in Matiari, Pakistan.

However, VT carriage decreased from 21.8% in 2014 to 12.7% in 2016 (p-value for
trend <0.001). A gradual decrease in prevalence of the three PCV13 specific serotypes 3,
6A, and 19A was also noticed as a group, but this was not statistically significant (p-value
for trend 0.141). However, the prevalence of NVT carriage increased significantly from
37.3% in 2014 to 57.2% in 2016 (p-value for trend <0.001). At the same time, the proportion
of fully vaccinated children (per verbal report or card verification) increased from 14.2 to
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Table 2. Vaccine type and non-vaccine type (NVT) carriage across three surveys in children
3–12 months of age in Matiari, Pakistan.
2014

2015

2016

(n= 224)

(n = 221)

(n = 220)

Positive for pneumococcus (n)

180

187

180

Prevalence of pneumococcus % (95% CI) *

80.3 (74.5–85.3)

84.6 (79.1–89.1)

81.8 (76.0–86.6)

49

43

28

21.8 (16.6–27.8)

19.4 (14.4–25.2)

12.7 (8.6–17.8)

131

144

152

65.1 (58.4–71.4)

69.0 (62.5–75.1)

Year

Vaccine type serotypes (n)
Prevalence of vaccine type serotypes % (95% CI)

β

NVT serotypes (n)
Prevalence of NVT serotypes % (95% CI)

γ

* p-value for trend = 0.340,

58.4 (51.7–65.0)
β

p-value for trend < 0.001,

γ

p-value for trend 0.020.

However, VT carriage decreased from 21.8% in 2014 to 12.7% in 2016 (p-value for
trend <0.001). A gradual decrease in prevalence of the three PCV13 specific serotypes 3,
6A, and 19A was also noticed as a group, but this was not statistically significant (p-value
for trend 0.141). However, the prevalence of NVT carriage increased significantly from
37.3% in 2014 to 57.2% in 2016 (p-value for trend <0.001). At the same time, the proportion
of fully vaccinated children (per verbal report or card verification) increased from 14.2 to
48.1% (p-value < 0.001). VT carriage in fully vaccinated children decreased from 9.3 to 7.5%
(p-value < 0.001, as depicted in Tables 3 and 4), whereas for unvaccinated children, VT
carriage decreased from 25.1 to 15.6% (p-value for trend <0.001).
Table 3. Vaccination status across the three surveys in children 3–12 months of age in Matiari.
PCV10 Vaccination Status

2014

2015

2016

Unvaccinated, % (95% CI) *

67.4 (60.8–73.5)

37.5 (31.1–44.3)

23.1 (17.7–29.3)

Partially vaccinated, % (95% CI) *

18.3 (13.4–24.0)

32.5 (26.4–39.1)

28.6 (22.7–35.0)

Fully vaccinated, % (95% CI) *

14.2 (9.9–19.5)

29.8 (23.9–36.3)

48.1 (41.4–54.9)

* p-value for trend <0.001 for all categories.

Table 4. VT Carriage rates by vaccination status across the three surveys.
PCV10 Vaccination Status

2014

2015

2016

Unvaccinated, % (95% CI) *

25.1 (18.4–32.8)

16.8 (9.5–26.6)

15.6 (7.0–28.5)

Partially vaccinated, % (95% CI) *

19.5 (8.8–34.8)

31.9 (21.4–43.9)

19.0 (10.2–30.9)

Fully vaccinated, % (95% CI) *

9.3 (1.9–25.0)

9.0 (3.4–18.7)

7.5 (3.3–14.3)

* p-value for trend <0.001.

Table 5 describes the association of different characteristics with a positive nasopharyngeal culture. In the final adjusted multivariate model, increasing age in months was
found to be significantly associated with culture positivity (aOR; 1.08, 95% CI 1.01, 1.16),
whereas children with two or more outpatient visits were less likely to have a positive
culture (aOR; 0.54, 95% CI 0.35, 0.89).
Table 6 shows the association of these characteristics with VT carriage. Those who
were not vaccinated and partially vaccinated were found to be at higher risk of carrying
a VT serotype when compared with fully vaccinated children ((aOR; 2.53, 95% CI 1.39,
4.63) and (aOR; 3.35, 95% CI 1.82, 6.16), respectively). On the other hand, being enrolled in
the last survey was negatively associated with VT carriage (aOR; 0.51, 95% CI 0.28, 0.93)
(Table 6).
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Table 5. Factors associated with a positive nasopharyngeal culture among study participants.
Culture Negative

Culture Positive

n = 118

n = 547

Unadjusted
OR(CI)

Adjusted
OR(CI)

6.9 ± 2.7

7.6 ± 2.7

1.1 (1.0–1.2)

1.1 (1.0–1.2)

Male

66 (56.4%)

268 (49.0%)

Reference

Female

51 (43.6%)

279 (51.0%)

1.3 (0.9–2.0)

Illiterate

76 (77.6%)

377 (84.7%)

Reference

1–5 Years

16 (16.3%)

51 (11.5%)

0.6 (0.3–1.1)

6–16 Years

6 (6.1%)

17 (3.8%)

0.6 (0.2–1.5)

No Education

59 (53.6%)

267 (52.1%)

Reference

Predictors
Age, months (Mean ± SD)
Gender

Education of Caretaker

Education of Primary wage earner

1–5 years

20 (18.2%)

121 (23.6%)

1.3 (0.7–2.3)

6–16 years

31 (28.2%)

124 (24.2%)

0.8 (0.5–1.4)

Total No. people in child0 s house, Median (IQR)

8 (6–11)

8 (6–11)

1.0 (0.9–1.0)

No. of rooms in child0 s house, Median (IQR)

1 (1–2)

1 (1–2)

1.0 (0.9–1.0)

Crowding index, Median (IQR)

5 (4–8)

5.5 (4–7.6)

1.0 (0.9–1.1)

None

107 (91.5%)

523 (95.6%)

Reference

One

8 (6.8%)

21 (3.8%)

0.5 (0.2–1.2)

Two or more

2 (1.7%)

3 (0.5%)

0.3 (0.05–1.9)

None

56 (47.9%)

337 (61.7%)

Reference

One

34 (29.1%)

108 (19.8%)

0.5 (0.3–0.9)

Two or more

27 (23.1%)

101 (18.5%)

0.6 (0.4–1.0)

Yes

59 (50.4%)

267 (48.8%)

1.0 (0.7–1.6)

No

58 (49.6%)

280 (51.2%)

Reference

Yes

46 (39.3%)

246 (45.0%)

1.3 (0.8–1.9)

No

71 (60.7%)

300 (54.8%)

Reference

Don0 t Know

0 (0.0%)

1 (0.2%)

-

Non-Vaccinated

59 (50.0%)

226 (41.3%)

0.6 (0.4–1.0)

Partially Vaccinated

30 (25.4%)

146 (26.7%)

0.8 (0.5–1.4)

Fully Vaccinated

29 (24.6%)

175 (32.0%)

Reference

2014

44 (37.3%)

180 (32.9%)

Reference

2015

34 (28.8%)

187 (34.2%)

1.3 (0.8–2.2)

2016

40 (33.9%)

180 (32.9%)

1.1 (0.7–1.8)

Hospital Admissions in the last year

Outpatient visits in the last month

Smoker in household

Exposed to smoke during cooking

PCV10 Vaccination Status

Year of Enrollment

0.5 (0.4–0.9)
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Table 6. Factors associated with the carriage of PCV10-serotype pneumococci among study participants.
PCV10
Negative

PCV10
Positive

n = 710

n = 180

7.6 (2.8)

7.0 (2.6)

0.9 (0.8–1.0)

Male

271 (49.8%)

63 (52.5%)

Reference

Female

273 (50.2%)

57 (47.5%)

0.9 (0.6–1.3)

Predictors
Age, months (Mean ± SD)

Unadjusted
OR(CI)

Adjusted
OR(CI)

Gender

Education of Caretaker
Illiterate

365 (81.7%)

88 (91.7%)

Reference

1–5 Years

60 (13.4%)

7 (7.3%)

0.5 (0.2–1.1)

6–16 Years

22 (4.9%)

1 (1.0%)

0.2 (0.2–1.4)

No Education

266 (52.3%)

60 (53.1%)

Reference

1–5 years

113 (22.2%)

28 (24.8%)

1.1 (0.6–1.8)

6–16 years

130 (25.5%)

25 (22.1%)

0.9 (0.5–1.4)

8 (6–11)

8 (6–11)

1.0 (0.9–1.0)

1 (1–2)

1 (1–2)

1.0 (0.9–1.0)

5.3 (4–7.6)

6 (4.1–8)

1.0 (0.9–1.1)

None

518 (95.2%)

112 (93.3%)

Reference

One

22 (4.0%)

7 (5.8%)

1.5 (0.6–3.5)

Two or more

4 (0.7%)

1 (0.8%)

1.2 (0.1–10.4)

None

323 (59.5%)

70 (58.3%)

Reference

One

121 (22.3%)

21 (17.5%)

0.8 (0.4–1.3)

Two or more

99 (18.2%)

29 (24.2%)

1.3 (0.8–2.2)

No

265 (48.7%)

61 (50.8%)

Reference

Yes

279 (51.3%)

59 (49.2%)

0.9 (0.6–1.3)

No

308 (56.6%)

63 (52.5%)

Reference

Yes

235 (43.2%)

57 (47.5%)

1.2 (0.7–1.7)

Non-Vaccinated

225 (41.3%)

60 (50.0%)

2.9 (1.6, 5.1)

2.4 (1.2–4.8)

Partially Vaccinated

133 (24.4%)

43 (35.8%)

3.5 (1.9, 6.5)

2.8 (1.3–5.9)

Fully Vaccinated

187 (34.3%)

17 (14.2%)

Reference

Ref

2014

175 (32.1%)

49 (40.8%)

Reference

2015

178 (32.7%)

43 (35.8%)

0.8 (0.5–1.3)

2016

192 (35.2%)

28 (23.3%)

0.5 (0.3–0.8)

Education of Primary wage earner

Total No. people in
No. of rooms in

child0 s

child0 s

house, Median (IQR)

house, Median (IQR)

Crowding index Median (IQR)
Hospital Admissions in the last year

Outpatient visits in the last month

Smoker in household

Exposed to smoke during cooking

PCV10 Vaccination Status

Year of Enrollment

0.5 (0.3–1.0)
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4. Discussion
In our study we saw a significant decline in the point prevalence of pneumococcal
Vaccine Type (VT) carriage after three years of PCV10 introduction in a previously vaccinenaïve rural population. When compared to the pre-introduction VT carriage rate of 26.6%
in the same population, a greater than 50% decline was observed. This decline was more
pronounced in the vaccinated group when compared to the partially/non-vaccinated group.
However, a significant decline in the non-vaccinated group after around half of the children
in the community were vaccinated hints towards an indirect effect of the vaccine.
Similar effects have been seen in populations across the world. Another study done
over four years (2014–2018) in the same rural population of Matiari, Pakistan, which
enrolled 3140 children younger than 2 years and followed a slightly different study design
showed a decline of greater than 50% in VT carriage, from 16.1% in 2014/15 to 9.6% in
2017/18 [25]. A four-year survey done in Fiji, from 2012 (pre-vaccination introduction) to
2015 (post vaccine introduction), showed a 63% reduction in PCV10 serotype carriage in
children aged 12–23 months. The percentage of participants who were PCV10-vaccinated
increased from zero in 2012 to 2% in 2013 to 95% in 2014 to 100% in 2015 in this study.
The researchers also observed a decrease in VT carriage in older unvaccinated children
and infants too young to be vaccinated [26]. A series of four annual cross-sectional study
done in Kilifi, Kenya, two were done before the introduction of PCV10, and two were
done afterwards, which showed that the carriage of VT serotypes dropped two-thirds in
both children and older individuals after vaccine coverage reached 79%. This study was
a milestone, as these findings suggested that PCV10 introduction can have a substantial
indirect effect on the unvaccinated population [27]. PCV10 was introduced in 2010 in
Brazil, and cross-sectional surveys done in 2010 and 2013 showed decreases in vaccine
type pneumococcal carriage from 19.8 to 1.8% at a vaccine coverage of 95% [28]. All these
studies, done in different parts of the world, in different ethnic populations and distinct
environments, have shown large decreases in vaccine-type pneumococcal carriage in both
vaccinated and un-vaccinated population· Because carriage is a precursor of disease, we can
reasonably infer that these decline in carriage rates would translate to a decline in disease.
Another important finding from our study is that the overall pneumococcal carriage
remained similar throughout. It was the composition of the serotypes that changed from
a predominantly vaccine type to a predominantly non-vaccine type. In baseline samples,
we see a higher prevalence of vaccine-type serotypes, but after vaccine introduction these
serotypes have been replaced by non-vaccine type (NVT) serotypes, keeping overall carriage rate the same. This phenomenon, known as serotype replacement, has also been
observed in other parts of the world. A study done in the Netherlands showed a large
reduction in vaccine serotypes after pneumococcal vaccination but also immediate and
complete replacement by non-vaccine pneumococcal (NVT) serotypes [29]. A study done in
Kenya five years after introduction of a vaccine showed a 76% prevalence of pneumococcal
carriage in children under 5 years [27] and another study in Mozambique two years after
the introduction of PCV10 reported an overall carriage rate of 84.8% in children under
5 years of age [27,30].
In our study we assessed predictors that are believed to influence pneumococcal
carriage, such as age, gender, previous hospital admissions, outpatient visits, and a patient’s
exposure to passive smoking. In the regression modeling, increasing age and number of
outpatient visits in the last year were found to be associated with overall carriage.
Existing scientific literature shows varied results regarding factors associated with
carriage; some studies agree with our findings while others showed no correlation with
carriage and these predictors. A study conducted in the Netherlands on the predictors of
pneumococcal colonization also found a decline in colonization with increasing age, which
may be related to maturation of immune system with age [31]. Ghaffar et al. showed that
passive smoking at home, large households, and crowding among teenagers were correlated
with higher pneumococcal carriage rates [32]. Another study done in the Netherlands also
examined predictors of pneumococcal carriage, but failed to show any correlation with
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specific factors [33]. Similar findings were reported from a study done in Cyprus, which
showed no association with previous antimicrobial use or history of upper respiratory
infection [34]. On the other hand, some studies have found a negative effect of previously
treated respiratory tract infection/antimicrobial use on carriage rate [35,36].
The introduction of vaccine directly benefited those who got the vaccine and indirectly
benefited those who didn’t get the vaccine. This is consistent with the herd effect of
immunization as exemplified by the Halloran model [37]. Vaccination status was found to
be negatively associated with VT carriage. The progressing years of the study were also
found to be negatively associated with VT carriage rate, which is again consistent with the
spilling over of beneficial effects of vaccine from the vaccinated to unvaccinated group.
A four-year cross-sectional survey done in Fiji found PCV-10 carriage to be negatively
associated with vaccination status and the year of enrollment in the study. In the same
study, predictors such as young age, urban residence, living with two or more children
under five years, low family income, symptoms of URTI, and exposure to household
cigarette smoke were found to be positively associated with VT carriage [38]. A study
done in Brazil, 3 years after the introduction of PCV10, showed that VT carriage declined
by >90%; with a reduction of 87.8% among partially vaccinated patients and 97% in the
fully vaccinated ones [28]. Thus, in light of the above findings and consistent literature, we
can infer that both vaccine coverage in the community and the number of years since the
introduction of the vaccine have a profound effect on VT carriage.
One of the strengths of our study was the availability of baseline carriage data as
a comparison group. We performed all surveys during the same months every year to
account for seasonal variations in carriage. Our study had several limitations. Vaccination
cards were not available for around 40% of the vaccinated children, thus we relied on
parental recall for vaccination status. Since our study was performed in one rural district of
Pakistan, the carriage rates may not be fully representative of other peri-urban and urban
settings. Nevertheless, these results provide evidence of the effect of PCV10 on carriage
in the same population over time which we believe would be replicable in other parts of
Pakistan. Moreover, in the context of PCV13 introduction in Pakistan’s EPI in early 2021,
our study provides invaluable baseline data for comparison with future surveys.
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